More Stories

Informist, Monday, Aug. 18, 2025

By P. Madhu Kumar and Narayana Krishna

MUMBAI/HYDERABAD – Glenmark Pharmaceuticals Ltd. is planning to focus more on high-margin and high-value branded products in India and also expects its Indian business to grow strong going forward despite a moderate performance in the segment in the June quarter, the company's management said in a post-earnings call with analysts on Monday. The management said that the company's overall revenue is likely to show robust growth from the December quarter of 2025-26 (Apr-Mar) backed by new product launches worldwide, especially in the US. 

The company's management remained confident in its diabetic portfolio and said sales in this segment will see a sharp jump in September, despite facing pricing and margin pressures during the June quarter. "The launch of both Tevimbra and Relenza, right, the two big products that took place in July... so, this quarter you should see good uptake of these two products since both of them are commercially launched now... we are very confident that the India business growth will be strong.

Glenmark Pharma posted a net profit of INR 468.71 million for the June quarter, hit by the one-time cost of INR 3.23 billion. Excluding the impact of the one-time cost, the drugmaker's net profit for the quarter was INR 3.7 billion.  The net profit, however, rose more than 10 times from a quarter ago as the company had incurred an exceptional cost of INR 3.73 billion in Jan-Mar. The drugmaker's consolidated revenue for the reporting quarter rose a meagre 0.6% on year to INR 32.64 billion.  

The management also said that the company plans to launch new respiratory products in the US and is currently looking for partners for some products, which are slated to launch in the second half of FY26. The company said the biggest launch in the respiratory segment would be Flovent, which is a long-term asthma control medicine. "And then, in addition, some of the partnership products we continue to commercialise, even in December and March quarters. So, I think, all in all, in the US, there is a clear trajectory to see higher growth going forward, compared to what we've had historically," the company's management said. 

Glenmark said that its net debt as of Jun. 30 stands at INR 15 billion. "In the first quarter, there was an increase in some of the sales realisation. Therefore, there was an increase in the gross debt," the management said. The company attributed the rise in debt to increased inventories, which was due to new launches in Europe being pushed to the September quarter from the latest quarter. The company said one-off severance payments and debtors added to the increase in overall debt of the company, but also assured that the numbers will stabilise in the upcoming quarters. 

When asked about any guidance for its earnings before interest, taxes, depreciation, and amortisation margin, the company said it expects EBITDA margin to stabilise around 23% from the December quarter. 

AT 1121 IST, shares of Glenmark Pharmaceuticals were trading down 3% at INR 1,985 on the National Stock Exchange.  End

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

Edited by Deepshikha Bhardwaj

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.